SEARCH

SEARCH BY CITATION

References

  • 1
    Kerlikowske K, Grady D, Rubin S, Sandrock C, Ernster V. Efficacy of screening mammography: a meta analysis. JAMA 1995; 273: 14954.
  • 2
    VainioH, BianchiniF, eds. IARC Handbooks of cancer prevention, vol. 7: Breast cancer screening. Lyon: IARC Press, 2002.
  • 3
    Ringash J. Canadian Task Force on Preventive Health Care. Preventive health care, 2001 update: screening mammography among women aged 40–49 years at average risk of breast cancer. Can Med Assoc J 2001; 164: 46976.
  • 4
    Tabar L, Faberberg G, Day N, Holmberg L. What is the optimum interval between mammographic screening examinations? An analysis based on the latest results of the Swedish two-county breast cancer screening trial. Br J Cancer 1987; 55: 54751.
  • 5
    Miller A, To T, Baines C, Wall C. The Canadian Breast Screening Study-1: breast cancer mortality after 11–16 years of follow-up. A randomized screening trial of mammography in women aged 40–49 years. Ann Intern Med 2002; 137: 30512.
  • 6
    Miller A, To T, Baines C, Wall C. Canadian National Breast Screening Study-2: 13 year results of a randomized trial in women aged 50–59 years. J Natl Cancer Inst 2000; 92: 14909.
  • 7
    Moss S. A trial to study the effect on breast cancer mortality of annual mammographic screening in women starting at age 40. Trial steering group. J Med Screen 1999; 6: 1448.
  • 8
    Breast screening frequency trial group. The frequency of breast cancer screening: results from the UKCCCR randomized trial. Eur J Cancer 2002; 38: 145864.
  • 9
    Paci E, Duffy S, Giorgi D, Crocetti E, Vezzosi V, Bianchi S, Roselli del Turco M. Quantification of the effect of mammographic screening on fatal breast cancers: the Florence programme 1990–96. Br J Cancer 2002; 87: 659.
  • 10
    Tabar L, Yen M, Vitak B, Chen H, Smith R, Duffy S. Mammography service screening and mortality in breast cancer patients: 20 year follow-up before and after introduction of screening. Lancet 2003; 361: 140510.
  • 11
    Otto S, Fracheboud J, Looman C, Broeders M, Boer R, Hendriks J, Verbeek A, de Koning H. National Evaluation Team for Breast Cancer Screening. Initiation of population based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review. Lancet 2003; 361: 141117.
  • 12
    Jonsson H, Tornberg S, Nystrom L, Lenner P. Service screening with mammography in Sweden. Acta Oncol 2000; 39: 61723.
  • 13
    Berry D, Cronin K, Plevritis S, Fryback D, Clarke L, Zelen M, Mandelblatt J, Yakovlev A, Habbema J, Feuer E. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353: 178492.
  • 14
    Jatoi I, Miller A. Why is breast cancer mortality declining. Lancet Oncol 2003; 4: 2514.
  • 15
    Olivotto I, Kan L, d'Yachkova Y, Burhenne LW, Hayes M, Hislop T, Worth A, Basco V, King S. Ten years of breast screening in the screening mammography program of British Columbia, 1988–97. J Med Screen 2000; 7: 1529.
  • 16
    Burhenne LW. The economics of screening mammography: cost containment methods in the screening mammography program of British Columbia. Semin Breast Dis 2001; 4: 3644.
  • 17
    Jaro M. Probabilistic linkage of large public health data files. Stat Med 1995; 14: 4918.
  • 18
    Sasieni P. On the expected number of cancer deaths during follow-up of an initially cancer-free cohort. Epidemiology 2003; 14: 10810.
  • 19
    McCullagh P, Nelder J. Generalized linear models, 2nd edn. London: Chapman and Hall, 1989. Monographs on statistics and applied probability ( CoxD et al., eds.), vol. 37., 1948.
  • 20
    Lawless J. Statistical models and methods for lifetime data. New York: Wiley, 1982.
  • 21
    Tetrad. P Census with ESRI mapping users guide. Vanc ouver: Tetrad Computer Applications, 2001. Canadian edition.
  • 22
    BC Cancer Agency. Screening Mammography Program of BC 2001/2002 Annual Report. Vancouver: BC Cancer Agency, 2002. 34p.
  • 23
    Hendrick R, Smith R, Rutledge J, Smart C. Benefit of screening mammography in women aged 40–49: a new meta-analysis of randomized controlled trials. J Natl Cancer Inst Monogr 1997; 22: 8792.
  • 24
    Nystrom L, Andersson I, Bjurstam N, Nordenskjold B, Rutqvist L. Long term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002; 359: 90919.
  • 25
    de Koning H, Boer R, Warmerdam P, Beemsterboer P, van der Maas P. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. J Natl Cancer Inst 1995; 87: 121723.
  • 26
    Larsson L-G, Andersson I, Bjurstam N, Faberberg G, Frisell J, Tabar L, Nystrom L. Updated overview of the Swedish randomized trials on breast cancer screening with mammography: age group 40–49 at randomization. Monogr Natl Cancer Inst 1997; 22: 5761.
  • 27
    Smith R. Breast cancer screening among women younger than age 50: a current assessment of the issues. CA Cancer J Clin 2000; 50: 31236.
  • 28
    Tabar L, Vitak B, Hsui-Hsi T, Ming-Fang Y, Duffy S, Smith R. Beyond randomized control trials: organized mammographic screening substantially reduces breast carcinoma mortality. Cancer 2001; 91: 172431.
  • 29
    Concato J, Shah N, Horwitz R. Randomized controlled trials, observational studies and the hierarchy of research designs. N Engl J Med 2000; 342: 198792.
  • 30
    Walter S. Mammographic screening: case-control studies. Ann Oncol 2003; 14: 119092.
  • 31
    Moss S, Summerley M, Thomas B, Ellman R, Chamberlain J. A case-control evaluation of the effect of breast cancer screening in the United Kingdom trial of early detection of breast cancer. J Epidemiol Community Health 1992; 46: 3624.
  • 32
    Duffy S, Cuzick J, Tabar L, Vitak B, Chen H, Yen M, Smith R. Correcting for non-compliance bias in case-control studies to evaluate cancer screening programmes. Appl Stat 2002; 51: 23543.
  • 33
    Goel V, Olivotto I, Hislop T, Sawka C, Coldman A, Holowaty E. Patterns of initial management of node-negative breast cancer in two Canadian provinces. British Columbia/Ontario Working Group. Can Med Assoc J 1997; 156: 2535.
  • 34
    Sawka C, Olivotto I, Coldman A, Goel V, Holowaty E, Hislop T. The association between population-based treatment guidelines and adjuvant therapy for node-negative breast cancer. British Columbia/Ontario Working Group. Br J Cancer 1997; 75: 153442.
  • 35
    Winer E, Morrow M, Osbourne C, Harris J. Malignant tumors of the breast. In: DeVitaV, HellmanS, RosenbergS, eds. Cancer: Principles and practice of oncology. Philadelphia: Lippincott, Williams and Wilkins, 2001. 16511717.